KIORA PHARMACEUTICALS
Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.
KIORA PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1998-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.kiorapharma.com
Total Employee:
11+
Status:
Active
Contact:
7813983811
Email Addresses:
[email protected]
Total Funding:
88.37 M USD
Technology used in webpage:
SPF Mobile Non Scaleable Content Microsoft Exchange Online IPv6 Microsoft Azure DNS Person Schema Google Google Cloud Gravatar Profiles CPanel SSL
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-03-07 | Jade Therapeutics | Jade Therapeutics acquired by Kiora Pharmaceuticals | N/A |
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Kiora Pharmaceuticals
Ventech
Ventech investment in Series D - Kiora Pharmaceuticals
Generis Capital Partners
Generis Capital Partners investment in Series D - Kiora Pharmaceuticals
Innoven Partners
Innoven Partners investment in Series D - Kiora Pharmaceuticals
Medicis Capital
Medicis Capital investment in Series D - Kiora Pharmaceuticals
Natixis Private Equity
Natixis Private Equity investment in Series D - Kiora Pharmaceuticals
Innoven Partners
Innoven Partners investment in Series C - Kiora Pharmaceuticals
Nexus Medical Partners
Nexus Medical Partners investment in Series C - Kiora Pharmaceuticals
Ventech
Ventech investment in Series C - Kiora Pharmaceuticals
Medicis Capital
Medicis Capital investment in Series C - Kiora Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-26 | EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. |
Official Site Inspections
http://www.kiorapharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.52 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kiora Pharmaceuticals"
About - Kiora Pharmaceuticals
He serves on the board for the charitable organization Optometry Giving Sight and has delivered over 1,000 lectures and authored over 1,000 papers. Previously, he served as co-chair for the …See details»
Management Team :: Kiora Pharmaceuticals, Inc. (KPRX)
[email protected] ©2024 Kiora Pharmaceuticals, Inc. About Technology KIO-301 KIO-104 Pipeline. Investors Overview News & Events Company Info Financial Info Stock Data SEC …See details»
Board of Directors :: Kiora Pharmaceuticals, Inc. (KPRX)
Previously he served as the Chief Medical Officer, Senior Vice President at Ora, Inc, an ophthalmic-specific contract research organization. Prior to this, he spent a decade at Allergan …See details»
Company Information :: Kiora Pharmaceuticals, Inc.
[email protected] ©2024 Kiora Pharmaceuticals, Inc. About Technology KIO-301 KIO-104 Pipeline. Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance Email Signup CONTACT. …See details»
EyeGate is Now Kiora Pharmaceuticals; Provides Update on
Nov 8, 2021 The company anticipates achieving several milestones for these programs that will drive value in the organization. ... For more information, please visit www.kiorapharma.com.See details»
Kiora Pharmaceuticals, Inc. | LinkedIn
Kiora Pharmaceuticals, Inc. (Kiora) is a clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases. Publicly traded on the NASDAQ under KPRX, our mission ...See details»
Kiora Pharmaceuticals, Inc. | LinkedIn
Kiora Pharmaceuticals, Inc. | 1,636 followers on LinkedIn. Developing advanced therapies for retinal disease | Kiora Pharmaceuticals, Inc. (Kiora) is a clinical stage biotech company …See details»
EyeGate is Now Kiora Pharmaceuticals; Provides Update on …
SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate ...See details»
Corporate Governance - Kiora Pharmaceuticals
[email protected] ©2021 Kiora Pharmaceuticals, Inc. About Technology KIO-301 KIO-104 Pipeline. Investors & News Overview News & Events Company Info Financial Info Stock Info …See details»
EyeGate is Now Kiora Pharmaceuticals; Provides Update on …
SALT LAKE CITY, UT, November 8, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: …See details»
Kiora Pharmaceuticals and Théa Open Develop and Commercialize …
Jan 31, 2024 Relations section of Kiora's website (ir.kiorapharma.com). Investors interested in a direct dial-in number may email [email protected] ahead of the call. A replay of the …See details»
Kiora Pharmaceuticals - Craft
Oct 18, 2024 Kiora Pharmaceuticals has 5 employees at their 1 location and $12.06 k in annual revenue in FY 2020. See insights on Kiora Pharmaceuticals including office locations, …See details»
Kiora Pharmaceuticals receives grant to fund novel clinical trial ...
Apr 13, 2024 Kiora Pharmaceuticals Inc has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients …See details»
EyeGate is Now Kiora Pharmaceuticals; Provides Update on …
Nov 8, 2021 The company anticipates achieving several milestones for these programs that will drive value in the organization. KIO-101, previously known as PP-001, is a next-generation …See details»
Investors - Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmic-focused biotech company with multiple active, clinical stage programs. Whilst the ophthalmology research community is incredibly innovative and …See details»
Kiora Pharmaceuticals Reports 2021 Results and Provides Business …
Apr 15, 2022 For more information, please visit www.kiorapharma.com. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made …See details»
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial …
SALT LAKE CITY, UT, Nov 15, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 …See details»
Kiora Pharmaceuticals, Inc. (KPRX)
Oct 29, 2024 [email protected] ©2024 Kiora Pharmaceuticals, Inc. About Technology KIO-301 KIO-104 Pipeline. Investors Overview News & Events Company Info Financial Info Stock …See details»
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial …
SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the …See details»